Clincosm LogoSign in Get a demo

Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)

Sponsor
Michele Reni (Other)
Overall Status
Recruiting
CT.gov ID
NCT04692740
Collaborator
(none)
30
Enrollment
1
Location
1
Arm
35.4
Anticipated Duration (Months)
0.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main objective of this trial is to explore the activity of chlorambucil, an alkylating agent commonly used in chronic lymphocytic leukemia treatment, in metastatic patients, gBRCA, including VUS, or DDR mutated, previously treated with a platinum-containing chemotherapy.

Condition or Disease Intervention/Treatment Phase
  • Drug: Chlorambucil, Oral, 2 Mg
 Phase 2

Detailed Description

Nowadays, treatment strategies for patients affected by metastatic pancreatic ductal adenocarcinoma (PDAC) are still very scant. Gemcitabine and fluoropyrimidine based chemotherapy regimens are standard I line chemotherapy. Recently, landmark genome-wide studies revealed the existence of a distinct subpopulation of PDAC with highly unstable genomic properties, due to mutations in DNA Damage Repair genes (DDR), in particular BRCA1/2 mutations. Germline mutations cause a deficiency in deoxyribonucleic acid (DNA) damage repair due to inhibition of DNA double-strand breaks repair by the mechanism of homologous recombination. Cancer cells rely on DNA repair to survive the damage induced by genotoxic stress and DNA repair enables cancer cells to accumulate genomic alterations that contribute to their aggressive phenotype. BRCA1/2 abrogation and homologous repair deficiency (HRD) confer sensitivity to DNA damage-inducing drugs, in particular those inflicting cytotoxic DNA crosslinks that interfere with DNA replication. The sensitivity of BRCA1/2-mutated tumors to platinum compounds has been validated in multiple pre-clinical and clinical studies. Nevertheless, similar lesions are induced by DNA-alkylating agents, which include mono-functional (e.g. mitomycin C) or bifunctional alkylators (e.g. chlorambucil). Small molecule inhibitors of poly(ADP-ribose) polymerase (PARP) have been recently developed and they showed an interesting activity and efficacy in breast, ovarian and pancreatic cancer tumors. Although platinum drugs and PARP inhibitors show initially good responses in the clinic, most patients acquire resistance to these drugs. Chlorambucil shows high selective toxicity against human cells and xenograft tumors with compromised BRCA1/2 function. Patients affected by metastatic ductal adenocarcinoma, pretreated with at least one previous platinum-based chemotherapy, will be treated with oral chlorambucil for 42 consecutive days After restaging, responder patients and those with stable disease will receive for 14 consecutive days every 28 days until disease progression (RECIST 1.1 criteria) or unbearable toxicity, patient refusal or medical decision.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Pilot Study of Chlorambucil in Pre-treated Metastatic Pancreatic Adenocarcinoma Patients Bearing a Germ Line BRCA or Other DNA Defects Repair (DDR) Mutations.
Actual Study Start Date :
Dec 18, 2020
Anticipated Primary Completion Date :
Jun 1, 2021
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Chlorambucil

Drug: Chlorambucil, Oral, 2 Mg
Eligible patients will be treated with Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1-6). After restaging, responder patients (complete or partial response) and those with stable disease will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days every 28 days until disease progression or unbearable toxicity, patient refusal or medical decision. Patients' clinical data will be collected pseudo-anonymously and a sequential identification code number will be assigned to each patient enrolled in the study.

Outcome Measures

Primary Outcome Measures

  1. Progression free survival evaluation [6 months]

    Evaluate the proportion of patients who are progression-free defined as progression according to RECIST 1.1 criteria or death. Progression free survival (PFS) is defined as the time between the date of registration and the date of documented radiological PD according to RECIST 1.1 criteria or death from any cause, whichever occurs first, or the date of last follow-up or last available tumour assessment if no further follow-up for disease progression is performed.

Secondary Outcome Measures

  1. Overall survival evaluation [36 months]

    Overall survival (OS) is defined as time between the date of registration and the date of death for any cause or the date they were last known to be alive

  2. Radiological response rate [6 months]

    Radiological response evaluation by using RECIST 1.1 criteria

  3. Biochemical response rate [6 months]

    Biochemical response evaluation by testing Ca19.9 marker

  4. Drug safety [6 months]

    Drug toxicity evaluation by using appropriate SAE report form

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Pathologically confirmed pancreatic adenocarcinoma

  2. Age ≥ 18 years

  3. ECOG PS 0-2

  4. Stage IV disease

  5. Identified genetic aberrations that are associated with homologous recombination deficiency (HRD)

  6. Cohort A: Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or suspected deleterious

  7. Cohort B: BRCA1 or BRCA2 mutations that are considered to be of uncertain/unknown significance (VUS)

  8. Cohort C: Patients with other identified genetic aberrations that are associated with HRD

  9. Adequate PFS during previous platinum-based chemotherapy for at least 4 months before progression

  10. Screening laboratory values:

Leukocytes > 3000/mmc Thrombocytes > 150000/mmc Hemoglobin > 10 g/dl Creatinine <2.0 times upper normal limit (unless normal creatinine clearance). Total bilirubin < 2.0 times upper normal limit (unless due to Gilbert's syndrome).

Alanine aminotransferase (ALT) < 3.0 times upper normal limit.

  1. Able to take oral medication

  2. Progression during or after platinum-based chemotherapy

  3. Other prior chemotherapy apart from first-line treatment for pancreatic cancer, are allowed, including maintenance treatment with PARP inhibitors

  4. More than 2 weeks since prior chemotherapy end

  5. Signed written informed consent

  6. QTc <450 msec or QTc <480 msec for patients with bundle branch block

Exclusion Criteria:

  1. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months prior to screening, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities

  2. Active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy

  3. Vaccination with vaccines called "live", since this treatment causes a drop of immunity defenses and a serious infection could result fatal.

  4. History of seizure, head trauma and treatment with anti-epileptogenic drugs

  5. Hypersensitivity to chlorambucil or to any excipients, in particular lactose

  6. Recent radiotherapy (at least 4 weeks) or previous treatment with other cytotoxic agents

  7. BRCA-mutated advanced pancreatic cancer who did not undergo maintenance with olaparib after platinum-based chemotherapy

  8. Mismatch repair (MMR)/high levels of microsatellite instability (MSI-H), or high levels of tumor mutational burden (TMB) pancreatic cancer who did not undergo immunotherapy with pembrolizumab monotherapy or any other anti-PD1 agent

  9. Concomitant PARP inhibitors therapy

  10. Life expectancy less than 3 months, in the opinion of the investigator

  11. Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible

  12. Symptomatic duodenal stenosis

  13. CT contrast medium allergy and claustrophobia to RM investigation

  14. Any significant medical condition laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study

  15. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study

  16. Any condition that confounds the ability to interpret data from the study

  17. Any familiar, sociologic or geographic conditions that can potentially interfere with the adhesion to the protocol or to the follow-up

  18. Pregnant or nursing. Adequate contraception is defined as oral hormonal birth control, intrauterine device, and male partner sterilization (if male partner is sole partner for that subject) and the double barrier method (condom or occlusive cap plus spermicidal agent).

  19. Concurrent treatment with other experimental drugs

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS San Raffaele Milan Italy 20132

Sponsors and Collaborators

  • Michele Reni

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Michele Reni, MD, IRCCS San Raffaele
ClinicalTrials.gov Identifier:
NCT04692740
Other Study ID Numbers:
  • PACT29
First Posted:
Jan 5, 2021
Last Update Posted:
Jan 5, 2021
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Michele Reni, MD, IRCCS San Raffaele
chlorambucil
BRCA mutations
DNA defect repair mutations
Additional relevant MeSH terms:
Adenocarcinoma
Chlorambucil

Study Results

No Results Posted as of Jan 5, 2021